8 results on '"Bea-Granell S"'
Search Results
2. Lipid profile of patients treated with evolocumab in Spanish hospital nephrology units (RETOSS NEFRO)
- Author
-
Goicoechea M, Alvarez V, Segarra A, Polaina M, Martin-Reyes G, Robles N, Escudero V, Orellana C, Bea Granell S, de Juan-Ribera J, Fernandez Lucas M, Grana J, Reque J, Sanchez Hernandez R, Villamayor S, and Gorriz J
- Subjects
Atherosclerotic cardiovascular disease ,Familial hypercholesterolemia ,Enfermedad cardiovascular ateroesclerótica ,c-LDL ,Nephrology units ,LDL-c ,Evolocumab ,Unidades de nefrología ,Hipercolesterolemia familiar - Abstract
BACKGROUND AND OBJECTIVE: To describe the clinical characteristics, the reasons for initiating therapy and the effects of treatment in the initial phase of evolocumab availability in the Nephrology Units of Spain. MATERIAL AND METHODS: Retrospective, observational and multicentric study that included patients initiating treatment with evolocumab (from February 2016 to August 2018), in 15 Nephrology Units in Spain. The demographic and clinical characteristics of the patients, the lipid lowering treatment and the evolution of the lipid profiles between 24 weeks pre-initiation and 12±4 weeks post-initiation of evolocumab were reviewed. RESULTS: Sixty patients were enrolled: 53.3% women; mean (SD) age, 56.9 (12.8) years, 45.0% with familial hypercholesterolemia (FH) (5.0% homozygous and 40.0% heterozygous) and 65.0% with atherosclerotic cardiovascular (CV) disease. The mean (SD) eGFR was 62.6 (30.0)ml/min/1.73m2 (51.7% of patients had eGFR2]), 50.0% had proteinuria (>300mg/g) and 10.0% had nephrotic syndrome. Other CV risk factors were hypertension (75.0%), diabetes (25.0%), and smoking (21.7%). A 40.0% of patients were statin intolerant. At evolocumab initiation, 41.7% of patients were on a high-intensity statin, 18.3% on moderate intensity statin and 50.0% were receiving ezetimibe. Mean (SD) LDL-c at evolocumab initiation was 179.7 (62.9)mg/dL (53.4% of patients with LDL-c=160mg/dL and 29.3%=190mg/dL). After 12 weeks, evolocumab resulted in LDL-c reductions of 60.1%. At week 12, 90.0% of patients reached LDL-c levels 2) and secondary prevention, with LDL-c levels above those recommended by the guidelines. Evolocumab used in clinical practice significantly reduced the LDL-c levels in all patients included in the study.
- Published
- 2021
3. Síndrome hemofagocítico reactivo a infección por citomegalovirus en paciente trasplantado renal
- Author
-
Bea Granell, S., Beneyto Castello, I., Ramos Escorihuela, D., Sánchez Plumed, J., Sánchez Pérez, P., Hernández-Jaras, J., and Rivas, S.
- Published
- 2011
4. Síndrome hemofagocítico reactivo a infección por citomegalovirus en paciente trasplantado renal
- Author
-
Bea Granell,S., Beneyto Castello,I., Ramos Escorihuela,D., Sánchez Plumed,J., Sánchez Pérez,P., Hernández-Jaras,J., and Rivas,S.
- Published
- 2011
5. Cytomegalovirus-associated haemophagocytic syndrome in a kidney transplant patient.
- Author
-
Bea Granell, S., Beneyto Castello, I., Ramos Escorihuela, D., Sánchez Plumed, J., Sánchez Pérez, P., Hernández-Jaras, J., and Rivas, S.
- Abstract
The article presents a case study of a 53-year-old man who is brought to the emergency department with fever, mild diffuse abdominal pain, asthenia, and anorexia. The patient is diagnosed with cytomegalovirus (CMV)-associated haemophagocytic syndrome. The study asserts that haemophagocytic syndrome is a certain complication following kidney transplantation.
- Published
- 2011
- Full Text
- View/download PDF
6. The metabolomic differential plasma profile between dialysates. Pursuing to understand the mechanisms of citrate dialysate clinical benefits.
- Author
-
Broseta JJ, Roca M, Rodríguez-Espinosa D, López-Romero LC, Gómez-Bori A, Cuadrado-Payán E, Bea-Granell S, Devesa-Such R, Soldevila A, Sánchez-Pérez P, and Hernández-Jaras J
- Abstract
Background: Currently, bicarbonate-based dialysate needs a buffer to prevent precipitation of bicarbonate salts with the bivalent cations, and acetate at 3-4 mmol/L is the most used. However, citrate is being postulated as a preferred option because of its association with better clinical results by poorly understood mechanisms. In that sense, this hypothesis-generating study aims to identify potential metabolites that could biologically explain these improvements found in patients using citrate dialysate. Methods: A unicentric, cross-over, prospective untargeted metabolomics study was designed to analyze the differences between two dialysates only differing in their buffer, one containing 4 mmol/L of acetate (AD) and the other 1 mmol/L of citrate (CD). Blood samples were collected in four moments (i.e., pre-, mid-, post-, and 30-min-post-dialysis) and analyzed in an untargeted metabolomics approach based on UPLC-Q-ToF mass spectrometry. Results: The 31 most discriminant metabolomic variables from the plasma samples of the 21 participants screened by their potential clinical implications show that, after dialysis with CD, some uremic toxins appear to be better cleared, the lysine degradation pathway is affected, and branched-chain amino acids post-dialysis levels are 9-10 times higher than with AD; and, on its part, dialysis with AD affects acylcarnitine clearance. Conclusion: Although most metabolic changes seen in this study could be attributable to the dialysis treatment itself, this study successfully identifies some metabolic variables that differ between CD and AD, which raise new hypotheses that may unveil the mechanisms involved in the clinical improvements observed with citrate in future research., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Broseta, Roca, Rodríguez-Espinosa, López-Romero, Gómez-Bori, Cuadrado-Payán, Bea-Granell, Devesa-Such, Soldevila, Sánchez-Pérez and Hernández-Jaras.)
- Published
- 2022
- Full Text
- View/download PDF
7. Impact of Acetate versus Citrate Dialysates on Intermediary Metabolism-A Targeted Metabolomics Approach.
- Author
-
Broseta JJ, Roca M, Rodríguez-Espinosa D, López-Romero LC, Gómez-Bori A, Cuadrado-Payán E, Devesa-Such R, Soldevila A, Bea-Granell S, Sánchez-Pérez P, and Hernández-Jaras J
- Subjects
- Acetates pharmacology, Acetylcarnitine, Bicarbonates pharmacology, Citrates pharmacology, Citric Acid Cycle, Glutamates, Glutarates, Glycerol, Humans, Inositol, Ketone Bodies, Lactates, Prospective Studies, Pyruvic Acid, Renal Dialysis adverse effects, Salts, Triglycerides, Citric Acid, Dialysis Solutions adverse effects
- Abstract
Acetate is widely used as a dialysate buffer to avoid the precipitation of bicarbonate salts. However, even at low concentrations that wouldn't surpass the metabolic capacity of the Krebs tricarboxylic acid (TCA) cycle, other metabolic routes are activated, leading to undesirable clinical consequences by poorly understood mechanisms. This study aims to add information that could biologically explain the clinical improvements found in patients using citrate dialysate. A unicentric, cross-over, prospective targeted metabolomics study was designed to analyze the differences between two dialysates, one containing 4 mmol/L of acetate (AD) and the other 1 mmol/L of citrate (CD). Fifteen metabolites were studied to investigate changes induced in the TCA cycle, glycolysis, anaerobic metabolism, ketone bodies, and triglyceride and aminoacidic metabolism. Twenty-one patients completed the study. Citrate increased during the dialysis sessions when CD was used, without surpassing normal values. Other differences found in the next TCA cycle steps showed an increased substrate accumulation when using AD. While lactate decreased, pyruvate remained stable, and ketogenesis was boosted during dialysis. Acetylcarnitine and myo-inositol were reduced during dialysis, while glycerol remained constant. Lastly, glutamate and glutarate decreased due to the inhibition of amino acidic degradation. This study raises new hypotheses that need further investigation to understand better the biochemical processes that dialysis and the different dialysate buffers induce in the patient's metabolism.
- Published
- 2022
- Full Text
- View/download PDF
8. Lipid profile of patients treated with evolocumab in Spanish hospital nephrology units (RETOSS NEFRO).
- Author
-
Goicoechea M, Álvarez V, Segarra A, Polaina M, Martín-Reyes G, Robles NR, Escudero V, Orellana C, Bea Granell S, de Juan-Ribera J, Fernández Lucas M, Graña JM, Reque J, Sánchez Hernández R, Villamayor S, and Górriz JL
- Subjects
- Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Cholesterol, LDL therapeutic use, Ezetimibe therapeutic use, Female, Hospitals, Humans, Male, Middle Aged, Retrospective Studies, Anticholesteremic Agents therapeutic use, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hypercholesterolemia chemically induced, Hypercholesterolemia drug therapy, Hyperlipoproteinemia Type II drug therapy, Nephrology
- Abstract
Background and Objective: To describe the clinical characteristics, the reasons for initiating therapy and the effects of treatment in the initial phase of evolocumab availability in the Nephrology Units of Spain., Material and Methods: Retrospective, observational and multicentric study that included patients initiating treatment with evolocumab (from February 2016 to August 2018), in 15 Nephrology Units in Spain. The demographic and clinical characteristics of the patients, the lipid lowering treatment and the evolution of the lipid profiles between 24 weeks pre-initiation and 12±4 weeks post-initiation of evolocumab were reviewed., Results: 60 patients were enrolled: 53.3% women; mean (SD) age, 56.9 (12.8) years, 45.0% with familial hypercholesterolemia (FH) (5.0% homozygous and 40.0% heterozygous) and 65.0% with atherosclerotic cardiovascular disease. The mean (SD) eGFR was 62.6 (30.0) ml/min/1.73m
2 (51.7% of patients had eGFR <60ml/min/1.73m2 [CKD stage>2]), 50.0% had proteinuria (>300mg/g) and 10.0% had nephrotic syndrome. Other CV risk factors were hypertension (75.0%), diabetes (25.0%), and smoking (21.7%). A 40.0% of patients were statin intolerant. At evolocumab initiation, 41.7% of patients were on a high intensity statin, 18.3% on moderate intensity statin and 50.0% were receiving ezetimibe. Mean (SD) LDL-c at evolocumab initiation was 179.7 (62.9) mg/dL (53.4% of patients with LDL-c ≥160mg/dL and 29.3% ≥190mg/dL). After 12 weeks, evolocumab resulted in LDL-c reductions of 60.1%. At week 12, 90.0% of patients reached LDL-c levels <100mg/dL, 70.0% <70mg/dL, and 55.0% <55mg/dL, while mean eGFR levels and statin use remained stable., Conclusion: In Nephrology Units of Spain, evolocumab was predominantly prescribed in patients with FH, chronic renal disease (CRD>2) and secondary prevention, with LDL-c levels above those recommended by the guidelines. Evolocumab used in clinical practice significantly reduced the LDL-c levels in all patients included in the study., (Copyright © 2022. Published by Elsevier España, S.L.U.)- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.